– New data highlight potential treatment benefit across multiple AxD symptom domains, reinforcing zilganersen’s positive impact on people living with this rare, often fatal neurological disease...
Webcast scheduled for Wednesday, April 29 at 8:30 a.m. Eastern Time
Ionis Pharmaceuticals and Waste Management insiders sell in early 2026, creating buying opportunities in their stocks while analysts raise price targets.
– PDUFA date set for September 22, 2026 –
– Lynne Parshall and Joseph Wender to retire at end of term in June 2026 and Peter Reikes to join Ionis Board –
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new data to be presented for DAWNZERA™ (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), including...
– PDUFA date set for June 30, 2026 –
Ionis Pharmaceuticals: Q4 Earnings Snapshot
- TRYNGOLZA ® generated $108 million in net product sales in 2025, the first year of launch – - Olezarsen sHTG launch preparations on track,...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Oppenheimer 36 ...